Identification

Name
Enalaprilat
Accession Number
DB09477
Type
Small Molecule
Groups
Approved
Description

Enalaprilat is the active metabolite of the orally available pro-drug, enalapril. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume. Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth. Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril.

Enalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible.

Structure
Thumb
Synonyms
  • Enalaprilat anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Enalaprilat dihydrateGV0O7ES0R384680-54-6MZYVOFLIPYDBGD-MLZQUWKJSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Enalaprilat Injection USPSolution1.25 mgIntravenousSterimax Inc2012-09-10Not applicableCanada
Vasotec IVSolution1.25 mgIntravenousSandoz Canada Incorporated1992-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EnalaprilatInjection1.25 mg/mLIntravenousCardinal Health2000-08-232017-11-14Us
EnalaprilatInjection, solution1.25 mg/mLIntravenousTeva Parenteral Medicines, Inc.2005-10-06Not applicableUs
EnalaprilatInjection1.25 mg/mLIntravenousWest Ward Pharmaceutical2008-12-23Not applicableUs
EnalaprilatInjection, solution1.25 mg/mLIntravenousTeva Parenteral Medicines, Inc.2005-10-06Not applicableUs
EnalaprilatInjection2.5 mg/2mLIntravenousWest Ward Pharmaceutical2008-12-23Not applicableUs
EnalaprilatInjection, solution1.25 mg/mLIntravenousHospira, Inc.2000-08-22Not applicableUs
Categories
UNII
Q508Q118JM
CAS number
76420-72-9
Weight
Average: 348.3936
Monoisotopic: 348.168521888
Chemical Formula
C18H24N2O5
InChI Key
LZFZMUMEGBBDTC-QEJZJMRPSA-N
InChI
InChI=1S/C18H24N2O5/c1-12(16(21)20-11-5-8-15(20)18(24)25)19-14(17(22)23)10-9-13-6-3-2-4-7-13/h2-4,6-7,12,14-15,19H,5,8-11H2,1H3,(H,22,23)(H,24,25)/t12-,14-,15-/m0/s1
IUPAC Name
(2S)-1-[(2S)-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}propanoyl]pyrrolidine-2-carboxylic acid
SMILES
[H][C@@](C)(N[C@@]([H])(CCC1=CC=CC=C1)C(O)=O)C(=O)N1CCC[C@@]1([H])C(O)=O

Pharmacology

Indication

Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical.

Associated Conditions
Pharmacodynamics

Enalaprilat injection results in the reduction of both supine and standing systolic and diastolic blood pressure, usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be anticipated in volume-depleted patients. The onset of action usually occurs within fifteen minutes of administration with the maximum effect occurring within one to four hours. The abrupt withdrawal of enalaprilat has not been associated with a rapid increase in blood pressure. The duration of hemodynamic effects appears to be dose-related. However, for the recommended dose, the duration of action in most patients is approximately six hours. Following administration of enalapril, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension.

Mechanism of action

Enalaprilat is the active metabolite of the orally available pro-drug, enalapril. Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II. As angiotensin II is responsible for vasoconstriction and sodium reabsorption in the proximal tubule of the kidney, down-regulation of this protein results in reduced blood pressure and blood fluid volume

TargetActionsOrganism
AAngiotensin-converting enzyme
inhibitor
Human
UB1 bradykinin receptorNot AvailableHuman
Absorption

Enalaprilat is poorly absorbed following oral administration, and is therefore only available as an intravenous injection.

Volume of distribution
Not Available
Protein binding

Enalaprilat is approximately 50% bound to plasma proteins. (Davies, et al. 1984)

Metabolism

Both enalapril and enalaprilat undergo renal excretion without further metabolism.

Route of elimination

Excretion of enalaprilat is primarily renal with more than 90 percent of an administered dose recovered in the urine as unchanged drug within 24 hours.

Half life

11 hr

Clearance

The disposition of enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. Renal clearance was 158 ± 47 ml/min.

Toxicity

Adverse experiences occurring in 0.5 to 1.0 percent of patients in controlled clinical trials included: myocardial infarction, fatigue, dizziness, fever, rash and constipation. Angioedema has also been reported in patients receiving enalaprilat, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalaprilat should be discontinued and appropriate therapy instituted immediately .

Rarer adverse effects that are less likely, but should be monitored for, include development of anaphylaxis, hypotension, agranulocytosis, hepatic failure, hyperkalemia, and persistent cough.

Furthermore, ACE inhibitors should be avoided during pregnancy as they can cause fetal and neonatal morbidity and death. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible. Use during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Enalaprilat.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Enalaprilat.Experimental
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Enalaprilat.Approved, Investigational
AcebutololAcebutolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Enalaprilat.Approved, Investigational
AcemetacinThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
Acetylsalicylic acidThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Enalaprilat.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Enalaprilat.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Aldesleukin.Approved
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Enalaprilat.Approved, Investigational
AliskirenAliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Enalaprilat.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Enalaprilat.Approved
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Enalaprilat.Experimental
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Enalaprilat.Approved
AloxiprinThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Aloxiprin.Experimental
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Enalaprilat.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Enalaprilat.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmbrisentanEnalaprilat may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Enalaprilat.Experimental, Investigational
AmifostineEnalaprilat may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAmiloride may increase the hyperkalemic activities of Enalaprilat.Approved
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Enalaprilat.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Enalaprilat.Approved
Aminosalicylic AcidThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Enalaprilat.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Enalaprilat.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with Enalaprilat.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Enalaprilat.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Enalaprilat.Approved, Illicit
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with Enalaprilat.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Enalaprilat.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Enalaprilat.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Amyl Nitrite.Approved
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Enalaprilat.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Enalaprilat.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Enalaprilat.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Enalaprilat.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Enalaprilat.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Apraclonidine.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Enalaprilat.Approved, Investigational
AprotininAprotinin may decrease the antihypertensive activities of Enalaprilat.Approved, Investigational, Withdrawn
AripiprazoleAripiprazole may increase the hypotensive activities of Enalaprilat.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Enalaprilat.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Enalaprilat.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Enalaprilat.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Enalaprilat.Approved
AvanafilAvanafil may increase the antihypertensive activities of Enalaprilat.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Enalaprilat.Withdrawn
AzathioprineThe risk or severity of anemia and severe leukopenia can be increased when Enalaprilat is combined with Azathioprine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Enalaprilat.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Enalaprilat.Approved, Investigational
AzosemideAzosemide may increase the hypotensive activities of Enalaprilat.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Enalaprilat.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Enalaprilat.Experimental
BarbitalBarbital may increase the hypotensive activities of Enalaprilat.Illicit
BarnidipineEnalaprilat may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Enalaprilat.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Enalaprilat.Experimental
BendroflumethiazideThe risk or severity of hypotension can be increased when Bendroflumethiazide is combined with Enalaprilat.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Enalaprilat.Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Enalaprilat.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Enalaprilat.Withdrawn
BenzthiazideThe risk or severity of hypotension can be increased when Benzthiazide is combined with Enalaprilat.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Enalaprilat.Approved
BepridilBepridil may increase the hypotensive activities of Enalaprilat.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Enalaprilat.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Enalaprilat.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Enalaprilat.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Enalaprilat.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Enalaprilat.Approved
BoceprevirThe serum concentration of Enalaprilat can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Enalaprilat.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Enalaprilat.Approved, Investigational
BQ-123Enalaprilat may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Enalaprilat.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Enalaprilat.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Enalaprilat.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Enalaprilat.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Enalaprilat.Approved, Investigational
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Enalaprilat.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Enalaprilat.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Enalaprilat.Experimental
BumetanideBumetanide may increase the hypotensive activities of Enalaprilat.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Enalaprilat.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Enalaprilat.Approved
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with Enalaprilat.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Enalaprilat.Approved
CadralazineCadralazine may increase the hypotensive activities of Enalaprilat.Experimental
CafedrineEnalaprilat may increase the hypotensive activities of Cafedrine.Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CanagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Canagliflozin is combined with Enalaprilat.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Enalaprilat.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Enalaprilat.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Enalaprilat.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Enalaprilat.Approved
Carbaspirin calciumThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Enalaprilat.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Enalaprilat.Withdrawn
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Enalaprilat.Approved, Vet Approved, Withdrawn
CarvedilolCarvedilol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Enalaprilat.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Enalaprilat.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Enalaprilat.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of hypotension can be increased when Chlorothiazide is combined with Enalaprilat.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Enalaprilat.Approved, Investigational, Vet Approved
ChlorthalidoneThe risk or severity of hypotension can be increased when Chlorthalidone is combined with Enalaprilat.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Enalaprilat.Approved
CicletanineEnalaprilat may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Enalaprilat.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Enalaprilat.Approved, Investigational
CiprofloxacinThe risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalaprilat.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Enalaprilat.Approved, Investigational
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Enalaprilat.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Enalaprilat.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Enalaprilat.Approved
CloranololEnalaprilat may increase the hypotensive activities of Cloranolol.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Enalaprilat.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Enalaprilat.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Enalaprilat.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Enalaprilat.Approved, Investigational
CyclopenthiazideThe risk or severity of hypotension can be increased when Cyclopenthiazide is combined with Enalaprilat.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Cyclosporine.Approved, Investigational, Vet Approved
DapagliflozinThe risk or severity of renal failure and hyperkalemia can be increased when Dapagliflozin is combined with Enalaprilat.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Enalaprilat.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Enalaprilat.Approved, Investigational
DelaprilEnalaprilat may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Enalaprilat.Approved
DersalazineThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Dersalazine.Investigational
DeserpidineEnalaprilat may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Enalaprilat.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Enalaprilat.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineEnalaprilat may increase the hypotensive activities of Dexniguldipine.Experimental
DiazoxideDiazoxide may increase the hypotensive activities of Enalaprilat.Approved
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with Enalaprilat.Experimental
DiclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Enalaprilat.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Enalaprilat.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalaprilat.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Enalaprilat.Experimental
DiflunisalThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Diflunisal.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Enalaprilat.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Enalaprilat.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Enalaprilat.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with Enalaprilat.Approved, Withdrawn
DinutuximabThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Dinutuximab.Approved, Investigational
DipyridamoleThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Dipyridamole.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Enalaprilat.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Enalaprilat.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Enalaprilat.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Enalaprilat.Approved, Investigational
DrospirenoneEnalaprilat may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Enalaprilat.Withdrawn
DuloxetineEnalaprilat may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Enalaprilat.Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Enalaprilat.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Enalaprilat.Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
EndralazineEndralazine may increase the hypotensive activities of Enalaprilat.Experimental
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Enalaprilat.Approved, Investigational
EpanololEnalaprilat may increase the hypotensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Enalaprilat.Approved
EpitizideThe risk or severity of hypotension can be increased when Epitizide is combined with Enalaprilat.Experimental
EplerenoneEplerenone may increase the hyperkalemic activities of Enalaprilat.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Enalaprilat.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Enalaprilat.Approved
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalaprilat.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Enalaprilat.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Enalaprilat.Approved
EsmololThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Enalaprilat.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Enalaprilat.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Enalaprilat.Approved, Investigational, Vet Approved
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Enalaprilat.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Enalaprilat.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Enalaprilat.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalaprilat.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Enalaprilat.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Enalaprilat.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Enalaprilat.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Enalaprilat.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Enalaprilat.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Enalaprilat.Approved
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Enalaprilat.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Enalaprilat.Experimental
FelodipineFelodipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Enalaprilat.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Enalaprilat.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Enalaprilat.Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Enalaprilat.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Enalaprilat.Experimental
Ferulic acidFerulic acid may increase the hypotensive activities of Enalaprilat.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Enalaprilat.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Enalaprilat.Approved, Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Enalaprilat.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Enalaprilat.Experimental
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Enalaprilat.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Enalaprilat.Experimental
FosinoprilFosinopril may increase the hypotensive activities of Enalaprilat.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Enalaprilat.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Enalaprilat.Approved, Investigational, Vet Approved
FurosemideFurosemide may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
GarlicThe serum concentration of Enalaprilat can be decreased when it is combined with Garlic.Approved, Nutraceutical
GuacetisalThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Enalaprilat.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Enalaprilat.Approved
GuanazodineEnalaprilat may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Enalaprilat.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
GuanoclorEnalaprilat may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzEnalaprilat may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanEnalaprilat may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Enalaprilat.Experimental
Hemoglobin crosfumarilThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Heparin.Approved, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Enalaprilat.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Enalaprilat.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Enalaprilat.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Enalaprilat.Experimental
HydralazineHydralazine may increase the hypotensive activities of Enalaprilat.Approved
HydrochlorothiazideThe risk or severity of hypotension can be increased when Hydrochlorothiazide is combined with Enalaprilat.Approved, Vet Approved
HydroflumethiazideThe risk or severity of hypotension can be increased when Hydroflumethiazide is combined with Enalaprilat.Approved, Investigational
IbuprofenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Enalaprilat.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Enalaprilat.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Enalaprilat.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Enalaprilat.Experimental
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Enalaprilat.Approved
IndapamideThe risk or severity of hypotension can be increased when Indapamide is combined with Enalaprilat.Approved
IndenololIndenolol may increase the hypotensive activities of Enalaprilat.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Enalaprilat.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Enalaprilat.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Enalaprilat.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Enalaprilat.Withdrawn
IprindoleThe serum concentration of Iprindole can be increased when it is combined with Enalaprilat.Experimental
IproclozideIproclozide may increase the hypotensive activities of Enalaprilat.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Enalaprilat.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Enalaprilat.Approved, Investigational
IronIron can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Iron Dextran.Approved, Vet Approved
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Enalaprilat.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Mononitrate.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Enalaprilat.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Enalaprilat.Experimental
KetanserinKetanserin may increase the hypotensive activities of Enalaprilat.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Enalaprilat.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Enalaprilat.Approved
LacidipineEnalaprilat may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Enalaprilat can be decreased when it is combined with Lanthanum carbonate.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Enalaprilat.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Enalaprilat.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Levobupivacaine.Approved, Investigational
LevodopaEnalaprilat may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Levosimendan.Approved, Investigational
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Enalaprilat.Approved
LinsidomineEnalaprilat may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Enalaprilat.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Enalaprilat.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Enalaprilat.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with Enalaprilat.Experimental
LofexidineLofexidine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Enalaprilat.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Enalaprilat.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Enalaprilat.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Enalaprilat.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Enalaprilat.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Enalaprilat.Approved, Investigational
MacitentanEnalaprilat may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Enalaprilat.Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineManidipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mannitol.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Enalaprilat.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Enalaprilat.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Enalaprilat.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Enalaprilat.Approved
MelitracenThe serum concentration of Melitracen can be increased when it is combined with Enalaprilat.Experimental, Investigational
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Enalaprilat.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Enalaprilat.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Enalaprilat.Approved, Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Enalaprilat.Approved
MethoserpidineEnalaprilat may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe risk or severity of hypotension can be increased when Methyclothiazide is combined with Enalaprilat.Approved
Methyl salicylateThe risk or severity of renal failure can be increased when Methyl salicylate is combined with Enalaprilat.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Enalaprilat.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Enalaprilat.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Enalaprilat.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Enalaprilat.Approved
MetipranololMetipranolol may increase the hypotensive activities of Enalaprilat.Approved
MetolazoneThe risk or severity of hypotension can be increased when Metolazone is combined with Enalaprilat.Approved
MetoprololMetoprolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MetyrosineEnalaprilat may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Enalaprilat.Investigational, Withdrawn
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Enalaprilat.Approved, Illicit
MinaprineMinaprine may increase the hypotensive activities of Enalaprilat.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Enalaprilat.Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Enalaprilat.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Enalaprilat.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Enalaprilat.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
MuzolimineEnalaprilat may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Enalaprilat.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Enalaprilat.Approved
NabiloneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Enalaprilat.Approved
NadololNadolol may increase the hypotensive activities of Enalaprilat.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Enalaprilat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Enalaprilat.Approved
NaftopidilEnalaprilat may increase the hypotensive activities of Naftopidil.Investigational
NaproxenThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Enalaprilat.Approved, Vet Approved
NebivololNebivolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Enalaprilat.Approved, Withdrawn
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Enalaprilat.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Enalaprilat.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
NicorandilNicorandil may increase the vasodilatory activities of Enalaprilat.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nifedipine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Enalaprilat.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Enalaprilat.Approved
NiguldipineNiguldipine may increase the hypotensive activities of Enalaprilat.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
NimesulideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Enalaprilat.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Enalaprilat.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Enalaprilat.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nitrous acid.Approved, Investigational
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Enalaprilat.Approved
ObinutuzumabEnalaprilat may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Enalaprilat.Withdrawn
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Enalaprilat.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Enalaprilat.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Enalaprilat.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Enalaprilat.Investigational
OmeprazoleOmeprazole can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Enalaprilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Enalaprilat.Vet Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Enalaprilat.Approved
OxprenololOxprenolol may increase the hypotensive activities of Enalaprilat.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Enalaprilat.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Paclitaxel.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Enalaprilat.Experimental, Nutraceutical
PapaverineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Papaverine.Approved, Investigational
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Enalaprilat.Approved
PargylinePargyline may increase the hypotensive activities of Enalaprilat.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Enalaprilat.Approved, Investigational
Patent BlueThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Patent Blue.Approved
PenbutololPenbutolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Enalaprilat.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Enalaprilat.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Enalaprilat.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Enalaprilat.Approved
PethidineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pethidine.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Enalaprilat.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Enalaprilat.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Enalaprilat.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Enalaprilat.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Enalaprilat.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Enalaprilat.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Enalaprilat.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Enalaprilat.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Enalaprilat.Approved
PindololPindolol may increase the hypotensive activities of Enalaprilat.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pipamperone.Approved, Investigational
PiretanidePiretanide may increase the hypotensive activities of Enalaprilat.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Enalaprilat.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Enalaprilat.Approved
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Enalaprilat.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Enalaprilat.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Enalaprilat.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Enalaprilat.Experimental
PolythiazideThe risk or severity of hypotension can be increased when Polythiazide is combined with Enalaprilat.Approved
Potassium bicarbonatePotassium bicarbonate may increase the hyperkalemic activities of Enalaprilat.Approved
Potassium cationPotassium may increase the hyperkalemic activities of Enalaprilat.Approved, Investigational
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Enalaprilat.Approved, Withdrawn
Potassium CitratePotassium Citrate may increase the hyperkalemic activities of Enalaprilat.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Pramipexole.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Enalaprilat.Experimental, Investigational
PrazosinPrazosin may increase the hypotensive activities of Enalaprilat.Approved
PregabalinThe risk or severity of angioedema can be increased when Enalaprilat is combined with Pregabalin.Approved, Illicit, Investigational
PrimidonePrimidone may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Enalaprilat.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Enalaprilat.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Enalaprilat.Approved, Investigational
PropafenoneThe risk or severity of hyperkalemia can be increased when Enalaprilat is combined with Propafenone.Approved
PropofolThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Propofol.Approved, Investigational, Vet Approved
PropranololEnalaprilat may increase the hypotensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Enalaprilat.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Enalaprilat.Experimental
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Enalaprilat.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Enalaprilat.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Quetiapine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Enalaprilat.Approved, Investigational
QuinethazoneThe risk or severity of hypotension can be increased when Quinethazone is combined with Enalaprilat.Approved
QuinineQuinine may increase the hypotensive activities of Enalaprilat.Approved
RamiprilRamipril may increase the hypotensive activities of Enalaprilat.Approved
RasagilineRasagiline may increase the hypotensive activities of Enalaprilat.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Enalaprilat.Approved
RescinnamineEnalaprilat may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Enalaprilat.Approved, Experimental, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Enalaprilat.Approved
RisperidoneEnalaprilat may increase the hypotensive activities of Risperidone.Approved, Investigational
RituximabEnalaprilat may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Enalaprilat.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Rotigotine.Approved
SacubitrilThe risk or severity of angioedema can be increased when Enalaprilat is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Enalaprilat.Withdrawn
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Enalaprilat.Approved
Salicylic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Enalaprilat.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Enalaprilat.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Enalaprilat.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Enalaprilat.Investigational
SaxagliptinThe risk or severity of angioedema can be increased when Saxagliptin is combined with Enalaprilat.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Enalaprilat.Approved, Investigational, Vet Approved
SelexipagEnalaprilat may increase the hypotensive activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Enalaprilat.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Enalaprilat.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Enalaprilat.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Enalaprilat.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Enalaprilat.Approved
SirolimusThe risk or severity of angioedema can be increased when Sirolimus is combined with Enalaprilat.Approved, Investigational
SitagliptinThe risk or severity of angioedema can be increased when Sitagliptin is combined with Enalaprilat.Approved, Investigational
SitaxentanEnalaprilat may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium aurothiomalateThe risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Enalaprilat is combined with Sodium aurothiomalate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of nephrotoxicity can be increased when Enalaprilat is combined with Sodium phosphate, monobasic.Approved
SotalolThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sotalol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Enalaprilat.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Enalaprilat.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Enalaprilat.Investigational
St. John's WortThe metabolism of Enalaprilat can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
StreptokinaseThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sufentanil.Approved, Investigational
SulfasalazineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Enalaprilat.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Enalaprilat.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Enalaprilat.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Enalaprilat.Experimental
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Enalaprilat.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Enalaprilat.Approved, Investigational
TalinololEnalaprilat may increase the hypotensive activities of Talinolol.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tamsulosin.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Enalaprilat.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Enalaprilat.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Enalaprilat.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Enalaprilat.Experimental, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Enalaprilat.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Enalaprilat.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Enalaprilat.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Terazosin.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Enalaprilat.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Enalaprilat.Approved, Investigational
TetrahydropalmatineEnalaprilat may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineEnalaprilat may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Enalaprilat.Approved
ThiamylalThiamylal may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Thioridazine.Approved, Withdrawn
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Enalaprilat.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Enalaprilat.Approved
TiboloneTibolone may increase the hypotensive activities of Enalaprilat.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Enalaprilat.Withdrawn
TimololTimolol may increase the hypotensive activities of Enalaprilat.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Enalaprilat.Investigational
TipranavirThe serum concentration of Enalaprilat can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of hypotension can be increased when Tizanidine is combined with Enalaprilat.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Enalaprilat.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolfenamic Acid is combined with Enalaprilat.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Enalaprilat.Approved
TolonidineEnalaprilat may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Enalaprilat.Approved
TolvaptanTolvaptan may increase the hyperkalemic activities of Enalaprilat.Approved
TorasemideTorasemide may increase the hypotensive activities of Enalaprilat.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Enalaprilat.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Enalaprilat.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Enalaprilat.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Enalaprilat.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneTriamterene may increase the hyperkalemic activities of Enalaprilat.Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Enalaprilat.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Enalaprilat.Experimental
TrichlormethiazideThe risk or severity of hypotension can be increased when Trichlormethiazide is combined with Enalaprilat.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Enalaprilat.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Enalaprilat.Approved, Investigational
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Enalaprilat.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Enalaprilat.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Enalaprilat.Investigational
Trolamine salicylateThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Enalaprilat.Approved
UdenafilUdenafil may increase the antihypertensive activities of Enalaprilat.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Enalaprilat.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Enalaprilat.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Enalaprilat.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Enalaprilat.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Enalaprilat.Approved
VerapamilThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Verapamil.Approved
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Enalaprilat.Approved, Investigational
VincamineEnalaprilat may increase the hypotensive activities of Vincamine.Experimental
XipamideEnalaprilat may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Enalaprilat.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Enalaprilat.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Enalaprilat.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Enalaprilat.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Enalaprilat.Approved, Investigational, Withdrawn
ZofenoprilEnalaprilat may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Enalaprilat.Withdrawn
Food Interactions
Not Available

References

General References
  1. Ulm EH: Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. Drug Metab Rev. 1983;14(1):99-110. [PubMed:6301792]
  2. Davies RO, Gomez HJ, Irvin JD, Walker JF: An overview of the clinical pharmacology of enalapril. Br J Clin Pharmacol. 1984;18 Suppl 2:215S-229S. [PubMed:6099737]
External Links
Human Metabolome Database
HMDB0041886
KEGG Drug
D03769
KEGG Compound
C11720
PubChem Compound
5462501
PubChem Substance
347827859
ChemSpider
4575429
BindingDB
50367254
ChEBI
4786
ChEMBL
CHEMBL577
HET
EAL
RxList
RxList Drug Page
Wikipedia
Enalaprilat
AHFS Codes
  • 24:32.04 — Angiotensin-converting Enzyme Inhibitors
PDB Entries
1uze / 2x90
FDA label
Download (2.99 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentCongestive Cardiomyopathy / High Blood Pressure (Hypertension)1
4CompletedBasic ScienceType 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableSalt-sensitive Hypertension1
Not AvailableCompletedHealth Services ResearchIdiopathic orthostatic hypotension / Spinal Cord Injuries (SCI)1
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionIntravenous1.25 mg/mL
InjectionIntravenous2.5 mg/2mL
Injection, solutionIntravenous1.25 mg/mL
SolutionIntravenous1.25 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.876 mg/mLALOGPS
logP-0.09ALOGPS
logP-1.1ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)3.13ChemAxon
pKa (Strongest Basic)7.83ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area106.94 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity90.06 m3·mol-1ChemAxon
Polarizability35.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Proline and derivatives / N-acyl-L-alpha-amino acids / Alpha amino acid amides / L-alpha-amino acids / Pyrrolidine carboxylic acids / N-acylpyrrolidines / Aralkylamines / Dicarboxylic acids and derivatives / Benzene and substituted derivatives / Tertiary carboxylic acid amides
show 8 more
Substituents
Alpha-dipeptide / N-acyl-alpha-amino acid / Proline or derivatives / N-acyl-alpha amino acid or derivatives / N-acyl-l-alpha-amino acid / Alpha-amino acid amide / Alpha-amino acid / Alpha-amino acid or derivatives / L-alpha-amino acid / N-acylpyrrolidine
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
dipeptide, dicarboxylic acid (CHEBI:4786)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent...
Gene Name
ACE
Uniprot ID
P12821
Uniprot Name
Angiotensin-converting enzyme
Molecular Weight
149713.675 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Peptide binding
Specific Function
This is a receptor for bradykinin. Could be a factor in chronic pain and inflammation.
Gene Name
BDKRB1
Uniprot ID
P46663
Uniprot Name
B1 bradykinin receptor
Molecular Weight
40494.29 Da
References
  1. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos EG: Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J Biol Chem. 2002 May 10;277(19):16847-52. Epub 2002 Mar 5. [PubMed:11880373]

Drug created on November 30, 2015 12:10 / Updated on August 14, 2018 04:32